Core Viewpoint - Jiangsu Nuotai Aosaikeno Biopharmaceutical Co., Ltd. (ST Nuotai) has been penalized by the China Securities Regulatory Commission (CSRC) for falsifying financial statements, including inflating revenue by 30 million yuan and profit by 25.9516 million yuan, which accounted for 20.64% of the total profit disclosed for the period [1][8][11]. Summary by Sections Administrative Penalty - The CSRC issued an administrative penalty decision against ST Nuotai, ordering it to correct its actions, issuing a warning, and imposing a fine of 47.4 million yuan. Six responsible individuals were fined between 1.5 million and 13 million yuan, totaling 28.8 million yuan [1][20]. Violations Identified - ST Nuotai's 2021 annual report contained false records, specifically regarding a technology transfer to Zhejiang Huabei Pharmaceutical Co., Ltd., which lacked commercial substance and should not have been recognized as revenue. This transaction was linked to a capital increase from ST Nuotai to Zhejiang Huabei [8][11][12]. - The company’s public offering documents also contained significant false information, particularly in the financial accounting section, which misrepresented the 2021 financial data [10][11]. Responsible Individuals - Key individuals involved included Zhao Dezhong (Vice Chairman), Zhao Deyi (Chairman), Jin Fuqiang (General Manager), and others, who failed to ensure the accuracy of the financial reports and were found to have participated in the misleading transactions [9][12][17]. Company Response and Future Actions - ST Nuotai acknowledged the violations and expressed intentions to strengthen internal controls and compliance processes. The company aims to improve the quality of information disclosure and maintain the interests of shareholders [25][26].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600581 证券简称：八一钢铁（维权） 公告编号：临2025-075 新疆八一钢铁股份有限公司关于公司、控股股东及相关当事人 收到中国证券监督管理委员会新疆监管局《行政处罚事先告知书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 新疆八一钢铁股份有限公司（以下简称"八一钢铁"或"公司"）及控股股东新疆八一钢铁集团有限公司 （以下简称"八钢集团"）于2025年11月7日收到中国证券监督管理委员会（以下简称"中国证监会"）下 发的《立案告知书》。因涉嫌信息披露违法违规，根据《中华人民共和国证券法》《中华人民共和国行 政处罚法》等法律法规，中国证监会决定对公司及八钢集团立案，具体情况详见公司于2025年11月8日 披露的《八一钢铁关于收到中国证券监督管理委员会立案告知书的公告》（公告编号：临2025-063）、 《八一钢铁关于中国证券监督管理委员会对控股股东立案调查的公告》（公告编号：临2025-064）。 2025年12月19日，公司、控股股东及相关当事人收到 ...

公司及实际控制人收到中国证监会出具的《立案告知书》。 12月19日，卓然股份(688121.SH)公告称，公司及实际控制人张锦红于2025年12月19日收到中国证监会 出具的《立案告知书》，因涉嫌信息披露违法违规等事项，中国证监会决定对公司及实际控制人张锦红 立案。目前公司各项经营活动和业务均正常开展。立案调查期间，公司及实际控制人将积极配合中国证 监会的相关工作，并严格按照相关法律法规和监管要求及时履行信息披露义务。 （文章来源：证券时报） 同日，公司收到上海证监局出具的《关于对上海卓然工程技术股份有限公司采取责令改正措施并对张锦 红、吴玉同、张笑毓采取出具警示函措施的决定》（沪证监决（ 2025 ）268 号）（以下简称《决定 书》）。 经查，公司存在以下违规事项: 2021年至2024年期间，公司在IPO募投项目实施过程中，违规支付部分募集资金，经由公司控股股东、 董事长张锦红有效控制的供应商或资金通道方银行账户流入体外资金池进行资金调配，部分资金在当日 或次日回流至公司非募集户，其余流向了张锦红间接控制的企业。公司未如实披露募集资金存放及实际 使用情况，亦未如实披露关联方非经营性资金往来情况。 公司上 ...

12月19日，卓然股份(688121)及实际控制人张锦红收到中国证监会出具的《立案告知书》，因涉嫌信息 披露违法违规等事项，中国证监会依法对卓然股份及实际控制人启动立案调查程序。公司于当日通过官 方公告作出回应，明确表示当前各项生产经营活动正常有序开展，业务运营未受实质性影响。在立案调 查期间，公司及实际控制人将全力配合监管机构的调查工作，严格遵循法律法规要求履行信息披露义 务，切实保障信息透明度与投资者知情权。 公司相关负责人表示，未来将始终坚守合规经营底线，持续完善内部控制体系，以更高标准规范运营管 理，确保公司治理水平不断提升。同时继续深化技术创新与绿色转型战略，聚焦核心业务拓展与新兴赛 道布局，通过提升技术壁垒与市场竞争力，实现经营业绩的稳健增长，以负责任的企业形象回馈投资者 与社会各界的信任。（厉平） ...

卓然股份(688121)12月19日公告，公司及实际控制人张锦红于12月19日收到中国证监会出具的《立案告 知书》，因涉嫌信息披露违法违规等事项，根据相关法律法规，中国证监会决定对公司及实际控制人张 锦红立案。目前公司各项经营活动和业务均正常开展。立案调查期间，公司及实际控制人将积极配合中 国证监会的相关工作，并严格按照相关法律法规和监管要求及时履行信息披露义务。 同日卓然股份公告，公司12月19日收到上海证监局出具的《关于对上海卓然工程技术股份有限公司采取 责令改正措施并对张锦红、吴玉同、张笑毓采取出具警示函措施的决定》（简称《决定》）。 《决定》显示，2021年至2024年期间，卓然股份在IP0募投项目实施过程中，违规支付部分募集资金， 经由公司控股股东、董事长张锦红有效控制的供应商或资金通道方银行账户流入体外资金池进行资金调 配，部分资金在当日或次日回流至公司非募集户，其余流向了张锦红间接控制的企业。公司未如实披露 募集资金存放及实际使用情况，亦未如实披露关联方非经营性资金往来情况。 卓然股份表示，公司及相关人员在收到上述行政监管措施决定书后，高度重视决定书中所指出的问题， 将严格按照上海证监局的要求， ...

Core Viewpoint - Zhuoran Co., Ltd. and its actual controller Zhang Jinhong are facing regulatory actions from the China Securities Regulatory Commission (CSRC) due to violations related to the use of IPO fundraising, which has been ongoing for four years [2][4]. Group 1: Regulatory Actions - Zhuoran Co., Ltd. received a "Notice of Investigation" from the CSRC and an administrative regulatory decision from the Shanghai Securities Regulatory Bureau on December 19 [2][5]. - The Shanghai Securities Regulatory Bureau's investigation revealed that from 2021 to 2024, Zhuoran Co., Ltd. misused part of its IPO fundraising by transferring funds through suppliers controlled by Zhang Jinhong, leading to a diversion of funds to external pools [4]. Group 2: Violations and Consequences - The investigation confirmed that Zhuoran Co., Ltd. engaged in serious violations by transferring IPO funds to external accounts and failing to disclose the actual use of these funds, violating the "Management Measures for Information Disclosure of Listed Companies" [4]. - The Shanghai Securities Regulatory Bureau mandated Zhuoran Co., Ltd. to submit a written rectification report within 30 days and issued warning letters to responsible personnel, including Zhang Jinhong, the former chairman [4]. Group 3: Company Response - Zhuoran Co., Ltd. stated that it takes the regulatory measures seriously and will comply with the requirements set forth by the Shanghai Securities Regulatory Bureau, ensuring that it will not affect daily operations [6]. - The company confirmed that all business activities are operating normally and that it will cooperate with the CSRC during the investigation [6].

Core Viewpoint - Recently, the Shanghai Stock Exchange listed company Renfu Pharmaceutical (600079.SH) announced that it is facing administrative penalties from the Hubei Regulatory Bureau of the China Securities Regulatory Commission (CSRC) for failing to timely disclose non-operating fund occupation by its controlling shareholder, with a cumulative amount of 12.785 billion yuan from 2020 to March 2022, along with significant omissions and false records in periodic reports. The regulatory bureau intends to issue a warning and impose a total fine of 8.5 million yuan on the company [2][27]. Group 1 - Renfu Pharmaceutical failed to timely disclose non-operating fund occupation, with a cumulative amount of 12.785 billion yuan from 2020 to March 2022 [6][32]. - The company’s 2020 annual report omitted the disclosure of 2.502 billion yuan of non-operating fund occupation, which accounted for 19.26% of the net assets recorded in the report [9][35]. - In 2021, the company reported a cumulative non-operating fund occupation of 8.179 billion yuan, representing 62.97% of the net assets [8][34]. Group 2 - The company did not disclose significant related party transactions in its 2022 annual report, including a total of 1.645 billion yuan in property asset purchases from a related party, which accounted for 9.17% of the net assets [11][37]. - Renfu Pharmaceutical's 2020, 2021, and 2022 semi-annual reports contained false records, leading to inflated net profits of 143 million yuan, 72 million yuan, and 91 million yuan respectively [12][38]. Group 3 - The controlling shareholder, Wuhan Contemporary Technology Industry Group, directed Renfu Pharmaceutical to provide funds for its own needs, constituting non-operating fund occupation [18][19]. - The regulatory bureau proposed fines totaling 8.5 million yuan against Renfu Pharmaceutical and its executives for the violations, including a 3.5 million yuan fine for the company itself [19][21].

登录新浪财经APP 搜索【信披】查看更多考评等级 受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我们！ 维权条件： 诺泰生物：根据相关司法解释，符合以下条件的投资者可发起索赔：于2022年4月28日-2024年10月24日 期间买入且有持仓，无论在2024年10月25日及之后是否卖出。（注：具体赔付范围由法院最终确定） （诺泰生物维权入口） （本文由上海市信本律师事务所合伙人赵敬国律师供稿，不代表新浪财经的观点。赵敬国律师，于1999 年取得律师资格，法学理论知识扎实，曾在高校任教。2004年起开始律师执业，承办过千余起各类诉讼 案件，积累了十分丰富的争议处理经验，尤其擅长处理证券纠纷、金融、不良资产等方面的业务。执业 至今，赵敬国律师代理投资者诉多家上市公司索赔案件，已经胜诉或已经获赔的案件包括中安科索赔、 中兵红箭索赔、步森服饰索赔、中潜股份索赔、奥瑞德索赔、獐子岛索赔、天神娱乐索赔、抚顺特钢索 赔、飞乐音响索赔、香溢融通索赔、延安必康索赔、欢瑞 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 登录新浪财经APP 搜索【信披】查看更多考评等级 受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我们！ 上海久诚律师事务所股票索赔律师许峰提示，立方数科（300344）虚假陈述引发的投资者索赔案还在推 进中，如果投资者因此受损，目前尚存索赔机会。（许峰律师专栏） 2025年12月15日，许峰律师代理的立方数科投资者索赔再向法院提交一次立案，此前已多次提交立案， 法院近期将陆续立案，目前律师团队还在继续推进后续案件的立案工作，还在继续接受其他投资者的索 赔委托。 2025年11月28日，立方数科公告因定期报告涉嫌信息披露违法违规，被证监会立案调查。公司及相关人 员于2025年11月28日收到证监会安徽监管局下发的《行政处罚及市场禁入事先告知书》。根据《告知 书》认定的事实，公司2021年、2022年 ...

Core Viewpoint - The article discusses the ongoing legal actions against Dinglong Culture (002502) for false disclosures, highlighting the potential for investor compensation due to the company's financial misreporting [1][2][3][4] Group 1: Legal Proceedings - The law firm Shanghai Jiucheng has submitted multiple claims to the Shantou Intermediate People's Court regarding investor compensation related to Dinglong Culture's false statements, with some cases already formally accepted by the court [1][2] - The legal team continues to accept new claims from investors who believe they are entitled to compensation [1][2] Group 2: Regulatory Findings - On September 11, 2024, Dinglong Culture received an administrative penalty from the Guangdong Regulatory Bureau of the CSRC, confirming violations in information disclosure [3] - The company was found to have inflated titanium concentrate production by 23,120.55 tons in 2021, with sales contracts executed without actual production or delivery, violating accounting standards [3] Group 3: Financial Misreporting - Dinglong Culture included inflated inventory and profits in its consolidated financial statements, leading to false disclosures in its 2021 annual report and 2022 semi-annual report [2][3] - In 2021, the company inflated inventory by 9,580,821.56 yuan and total profit by 2,147,160.01 yuan, which constituted 16.30% of the reported profit for that period [2][3] - For the first half of 2022, the inflated operating revenue was 45,778,689.00 yuan and inflated profit was 37,903,539.96 yuan, representing 19.72% and 64.10% of the reported figures, respectively [2][3] Group 4: Investor Compensation Opportunities - Investors who purchased Dinglong Culture stock between April 30, 2022, and April 29, 2023, and sold or held the stock after April 29, 2023, may still have opportunities for compensation [4]